Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
12/2003
12/04/2003CA2784937A1 Ccr9 inhibitors and methods of use thereof
12/04/2003CA2493902A1 Decoy composition for treating and preventing inflammatory disease
12/04/2003CA2490542A1 Fas peptide mimetics and uses thereof
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487246A1 Novel uses of cephaibols
12/04/2003CA2487167A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486376A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2484000A1 Neutralizing human anti-igfr antibody
12/04/2003CA2478833A1 Anti-.alpha.v.beta.6 antibodies
12/03/2003EP1366771A2 Use of the neurotoxic compnent of botulinum toxins as a medicament
12/03/2003EP1366770A2 Use of botulinum toxin for treating muscle-associated pain
12/03/2003EP1366180A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366161A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof
12/03/2003EP1366150A2 Use of protein histidine phosphatase
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366050A2 Condensed pyrazindione derivatives as pde inhibitors
12/03/2003EP1366049A2 Pirazino[1'2':1,6]pyrido[3,4-b]indole derivatives
12/03/2003EP1366047A1 Thiazole compounds as tgf-beta inhibitors
12/03/2003EP1366024A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
12/03/2003EP1366020A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity
12/03/2003EP1366018A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
12/03/2003EP1365800A2 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/03/2003EP1365798A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
12/03/2003EP1365761A1 Therapeutic combination of amlodipine and benazepril
12/03/2003EP1365760A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/03/2003EP1257555B1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/03/2003EP1150963B1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
12/03/2003EP1117659B1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
12/03/2003EP1064306B1 Nephrin gene and protein
12/03/2003EP1015437B1 Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals
12/03/2003CN1460105A 黄嘌呤磷酸二酯酶v抑制剂 Xanthine phosphodiesterase inhibitor v
12/03/2003CN1460025A Immunomodulatory human MHC class Ôàí antigen-binding polypeptides
12/03/2003CN1459459A Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of rainbow conk
12/03/2003CN1459448A Preparation method of red sageroot total phenolic acid and its use
12/03/2003CN1459299A Medicine for treating toxuria, and its prepn. method
12/03/2003CN1129577C 维生素d3衍生物 Derivatives of vitamin d3
12/03/2003CN1129428C Endothelin receptor antagonists
12/02/2003US6656971 Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions
12/02/2003US6656969 Methods and compositions for inhibiting the proliferation of prostate cancer cells
12/02/2003US6656966 Nitrosated and nitrosylated taxanes, compositions and methods of use
12/02/2003US6656954 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity
12/02/2003US6656945 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
12/02/2003US6656939 Pyrazole compounds useful as protein kinase inhibitors
12/02/2003US6656937 Substituted glutarimides and their use as inhibitors of IL-12 production
12/02/2003US6656933 Novel compounds which inhibit production of cytokines involved in inflammatory processes
12/02/2003US6656716 Polypeptide fragments of human PAK5 protein kinase
12/02/2003US6656681 Polycystic kidney disease 12 gene and uses thereof
12/02/2003CA2224284C Use of 19-nor-vitamin d compounds for the prevention of hyperphosphatemia in kidney disorder patients
12/02/2003CA2132865C Transdermal administration of oxybutynin
11/2003
11/27/2003WO2003097852A2 Assay for identifying inhibitors of fc gamma riii signaling
11/27/2003WO2003097849A1 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
11/27/2003WO2003097799A2 HTLV-I TAX INDUCED KILLING OF p53 NULL CANCER CELLS
11/27/2003WO2003097659A1 6-11 bicyclic ketolide derivatives
11/27/2003WO2003097658A2 Compounds and methods for inhibiting selectin-mediated function
11/27/2003WO2003097641A2 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
11/27/2003WO2003097639A1 Benzoxazine and benzoxazinone substituted triazoles
11/27/2003WO2003097636A1 Novel compounds and their use
11/27/2003WO2003097610A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
11/27/2003WO2003097608A2 Opioid and opioid-like compounds and uses thereof
11/27/2003WO2003097601A1 Cyanoguanidine prodrugs
11/27/2003WO2003097597A2 Indole derivatives and the use thereof as cb2 receptor ligands
11/27/2003WO2003097591A1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
11/27/2003WO2003097586A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003WO2003097104A1 Treatment and prevention of tissue damage
11/27/2003WO2003097098A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003WO2003097082A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
11/27/2003WO2003097073A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
11/27/2003WO2003097071A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003WO2003097067A1 Combination of an ace inhibitor, a calcium channel blocker and a diuretic
11/27/2003WO2003097060A1 Oral therapeutic or preventive drugs for pollakiuria and urinary incontinence or oral sleep inducers, containing tropolone derivatives
11/27/2003WO2003097047A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
11/27/2003WO2003097045A1 Combination of organic compounds
11/27/2003WO2003097029A1 Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives
11/27/2003WO2003070765A3 Growth hormone fusion protein
11/27/2003WO2003070157A3 Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
11/27/2003WO2003066594A3 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/27/2003WO2003065983A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/27/2003WO2003064622A3 Aggrecanase molecules
11/27/2003WO2003053354A3 Fused cyclic modulators of nuclear hormone receptor function
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003032964A3 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
11/27/2003WO2003022852A3 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
11/27/2003WO2003014064A8 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2002092004A8 Use of hmg fragment as anti-inflammatory agents
11/27/2003WO2002086156A3 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002063010A3 Method of producing recombinant antibodies against tumors
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003US20030220494 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/27/2003US20030220493 Selectively inhibit binding to the alpha -1a adrenergic receptor; chemical intermediates
11/27/2003US20030220468 Modified forms of pharmacologically active agents and uses therefor
1 ... 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 ... 562